US, UK approve Roche’s USD4.3B purchase of gene therapy group Spark

ZURICH (AFP) – Swiss pharmaceuticals giant Roche said it had received the approval from competition authorities to acquire United States (US) gene-therapy group Spark, after the two companies reached a multibillion-dollar deal earlier this year.

Founded in 2013, Spark Therapeutics specialises in a new and growing segment of medicine for genetic diseases such as blindness, haemophilia, and neurodegenerative conditions.

The US Federal Trade Commission (FTC) “unconditionally cleared Roche’s pending acquisition of Spark”, the Swiss company said in a statement on Monday.